## Stefano Arcangeli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9039098/publications.pdf

Version: 2024-02-01

45 papers

1,339 citations

16 h-index 36 g-index

45 all docs

45 docs citations

45 times ranked

1546 citing authors

#	Article	IF	Citations
1	A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients With High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 11-18.	0.8	243
2	Updated Results and Patterns of Failure in a Randomized Hypofractionation Trial for High-risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1172-1178.	0.8	187
3	Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. Oncologist, 2012, 17, 1100-1107.	3.7	185
4	Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. Journal of Clinical Oncology, 2017, 35, 1891-1897.	1.6	141
5	Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiation Oncology, 2013, 8, 171.	2.7	98
6	Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review. Critical Reviews in Oncology/Hematology, 2013, 88, 550-563.	4.4	52
7	Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Critical Reviews in Oncology/Hematology, 2012, 84, 101-108.	4.4	44
8	Extreme hypofractionation for early prostate cancer: Biology meets technology. Cancer Treatment Reviews, 2016, 50, 48-60.	7.7	40
9	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiation Oncology, 2020, 15, 92.	2.7	31
10	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treatment Reviews, 2021, 98, 102206.	7.7	30
11	From radiobiology to technology: what is changing in radiotherapy for prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 553-564.	2.4	28
12	Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?. Nature Reviews Urology, 2016, 13, 400-408.	3.8	27
13	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. Tumori, 2013, 99, 637-649.	1.1	18
14	"Hit the primary― A paradigm shift in the treatment of metastatic prostate cancer?. Critical Reviews in Oncology/Hematology, 2016, 97, 231-237.	4.4	18
15	Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiologia Medica, 2021, 126, 1117-1128.	7.7	18
16	Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Cancer Treatment Reviews, 2021, 95, 102176.	7.7	17
17	A cast of shadow on adjuvant radiotherapy for prostate cancer: A critical review based on a methodological perspective. Critical Reviews in Oncology/Hematology, 2016, 97, 322-327.	4.4	12
18	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 C Reviews in Oncology/Hematology, 2019, 134, 104-119.	0 0 rgBT /O 4.4	verlock 10 Tf

Reviews in Oncology/Hematology, 2019, 134, 104-119.

#	Article	IF	Citations
19	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. Radiotherapy and Oncology, 2021, 164, 104-114.	0.6	10
20	Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?. Reports of Practical Oncology and Radiotherapy, 2015, 20, 425-429.	0.6	9
21	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. Radiotherapy and Oncology, 2020, 147, 229-230.	0.6	9
22	Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2021, 162, 103345.	4.4	9
23	Toxicity of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: A Potential Comparison Bias. Journal of Clinical Oncology, 2014, 32, 3454-3454.	1.6	8
24	Optimal scheduling of hypofractionated radiotherapy for localized prostate cancer: A systematic review and metanalysis of randomized clinical trials. Cancer Treatment Reviews, 2018, 70, 22-29.	7.7	8
25	Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. Tumori, 2019, 105, 516-523.	1.1	8
26	High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses – 14 years of single-centre experience. Journal of Contemporary Brachytherapy, 2020, 12, 533-539.	0.9	8
27	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq1 1 0 Reviews in Oncology/Hematology, 2019, 134, 87-103.	.784314 rş 4.4	gBT  Over o
28	Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation,) Tj ETQq0 0 0 rg	BT_/Overloo	ck 10 Tf 50
29	and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2021, 159, 103235.  Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking. Radiation Oncology, 2021, 16, 180.	2.7	7
30	Intrafraction Prostate Motion Management During Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy. Frontiers in Oncology, 2022, 12, 883725.	2.8	7
31	Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era. Critical Reviews in Oncology/Hematology, 2015, 93, 136-148.	4.4	6
32	The Italian Association of Radiotherapy and Oncology Recommendation for Breast Tumor Recurrence: Grades of Recommendation, Assessment, Development and Evaluation Criteria. Journal of Breast Cancer, 2021, 24, 241.	1.9	6
33	Loco-regional adjuvant radiation therapy in breast cancer patients with positive axillary lymph-nodes at diagnosis (CN2) undergoing preoperative chemotherapy and with complete pathological lymph-nodes response. Development of GRADE (Grades of recommendation, assessment, Development) Tj ETQq1	. <b>½.0.</b> 7843	1 <b>4</b> rgBT /0\
34	Oncology (AIRO). Breast, 2021, 55, 119-127.  Back to (new) normalityâ€"A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2. Medical Oncology, 2020, 37, 108.	2.5	5
35	Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy. Strahlentherapie Und Onkologie, 2022, 198, 448-457.	2.0	5
36	How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). Cancers, 2021, 13, 2702.	3.7	4

#	Article	IF	CITATIONS
37	In reply to Fiorino et al.: The central role of the radiation oncologist in the multidisciplinary & multiprofessional model of modern radiation therapy. Radiotherapy and Oncology, 2021, 155, e20-e21.	0.6	3
38	Adjuvant radiotherapy and radioiodine treatment for locally advanced differentiated thyroid cancer: systematic review and meta-analysis. Tumori, 2021, 107, 489-497.	1.1	3
39	Almost one year of COVID-19 pandemic: how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study. Tumori, 2022, 108, 177-181.	1.1	2
40	Stereotactic radiotherapy for liver oligometastases. Reports of Practical Oncology and Radiotherapy, 2022, 27, 32-39.	0.6	2
41	Unmet needs in the management of unresectable stage III non-small cell lung cancer: a review after the â€radio talk' webinars. Expert Review of Anticancer Therapy, 2022, 22, 549-559.	2.4	1
42	Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture?. Cancer, 2018, 124, 3618-3619.	4.1	0
43	Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Journal of Cancer Research and Clinical Oncology, 2021, 147, 793-802.	2.5	0
44	Safety culture to improve accidental events reporting in radiotherapy. Journal of Radiological Protection, 2021, 41, .	1.1	0
45	Postoperative radiotherapy (PORT) in NSCLC: The end of a love? It is never too good to trust what appears. Lung Cancer, 2022, , .	2.0	0